Printer Friendly

Cancer-fighting cell receptor cloned.

Cancer-fighting cell receptor cloned

Researchers have deciphered the genetic code for a receptor molecule that serves as the docking site for a naturally occurring cancer-fighting compound. The achievement may help explain why treatment with the compound, called tumor necrosis factor (TNF), has yielded inconsistent results in cancer patients, and may lead to improved cancer therapies, the researchers say.

Produced in small quantities by white blood cells, TNF can directly attack tumor cells and can activate other immune-system cells to attack cancerous tissues. But when physicians give high doses to cancer patients, TNF sometimes helps, sometimes has no effect, and sometimes induces severe side effects.

The key differences between TNF's good and bad sides may become clear with a better understanding of the compound's receptor, says Gale Granger of the University of California, Irvine, who led the effort to clone the TNF receptor.

While TNF receptors normally reside on the membrances of white blood cells, some cancer patients have circulating versions of the receptor in their blood. Grange suggests that these soluble receptors may "mop up" therapeutic doeses of the drug before it gets to its tumorous target. Knowledge gained from cloning the receptor may someday enable physicians to "get rid of the circulating receptors first, give the TNF [to a cancer patient], then add more receptors" to sop up any excess that could cause side effects, he says. Moreover, further analysis of the receptor's structure may reveal details about how it functions, providing an opportunity to modify its activity, the researchers assert in the April 20 CELL.
COPYRIGHT 1990 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1990, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Science News
Date:Apr 28, 1990
Previous Article:Rescuing red cells to boost blood supply.
Next Article:Termites not to blame for methane.

Related Articles
Fooling cancer with tech wizardry.
Allergy-triggering receptor made en masse.
Researchers clone anti-inflammatory protein.
Cloning the genes for A and B blood types.
Dopamine receptor genes found, cloned.
Blocking breast cancer: do faulty estrogen receptors make a meaner, tougher tumor?
Gene therapy cancer treatment begins.
Killing tumors with fewer side effects.
Dolly was lucky: scientists warn that cloning is too dangerous for people.
Attack of the clones: as cloning technology marches forward, state legislatures are faced with some hard decisions.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters